long intergenic non-protein coding RNA 1681Genealiases: []
Q-omics provides the consensus-scored LINC01681 profile across patient tissues and cancer cell-line models. LINC01681 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01681 is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, LINC01681 RNA expression shows 5,709 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, LUAD, and STAD as cancer lineages where LINC01681 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01681 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01681 survival associations across molecular data types. LINC01681 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01681 RNA expression–survival associations across cancer types. High LINC01681 expression shows unfavorable associations in KIRC, KIRP, THCA, LUAD and LGG, but favorable associations in ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01681 RNA expression.
This table summarizes LINC01681 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01681. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01681 shows lower tumor expression in KIRP and KIRC and higher tumor expression in LUAD, LIHC, LUSC and HNSC. The LUAD box plot shows higher LINC01681 RNA expression in tumor versus normal tissue (log2 FC = +0.090, t-test p = .001).
This table shows molecular features associated with LINC01681 in patient tissues and cancer cell lines. In patient samples, LINC01681 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
